Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Revenue Multiple | 33.2x - 36.7x | 34.9x |
| Selected Fwd Revenue Multiple | 34.5x - 38.1x | 36.3x |
| Fair Value | ₺72.44 - ₺80.08 | ₺76.26 |
| Upside | -10.4% - -1.0% | -5.7% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Consus Enerji Isletmeciligi ve Hizmetleri A.S. | CONSE | IBSE:CONSE |
| Kartal Yenilenebilir Enerji Uretim A.S. | KARYE | IBSE:KARYE |
| Biotrend Cevre ve Enerji Yatirimlari A.S. | BIOEN | IBSE:BIOEN |
| Zorlu Enerji Elektrik Üretim A.S. | ZOREN | IBSE:ZOREN |
| Aydem Yenilenebilir Enerji A.S. | AYDEM | IBSE:AYDEM |
| Pamukova Yenilenebilir Elektrik Uretim A.S. | PAMEL | IBSE:PAMEL |
| Select LTM Revenue Multiple | ||||||||
| Benchmark Companies | ||||||||
| CONSE | KARYE | BIOEN | ZOREN | AYDEM | PAMEL | |||
| IBSE:CONSE | IBSE:KARYE | IBSE:BIOEN | IBSE:ZOREN | IBSE:AYDEM | IBSE:PAMEL | |||
| Historical Revenue Growth | ||||||||
| 5Y CAGR | NM- | 58.1% | 96.4% | 29.3% | 40.6% | 54.0% | ||
| 3Y CAGR | 54.4% | 63.3% | 84.5% | 36.6% | 74.4% | 93.4% | ||
| Latest Twelve Months | -19.7% | 48.2% | -16.6% | -24.7% | -28.3% | -15.1% | ||
| Historical EBIT Profit Margin | ||||||||
| 5 Year Average Margin | -3.3% | 41.3% | 10.7% | 11.2% | 43.1% | 169.3% | ||
| Prior Fiscal Year | -20.0% | 18.3% | 1.9% | 6.3% | 32.4% | 202.2% | ||
| Latest Fiscal Year | 4.2% | 39.3% | -13.7% | 3.9% | 15.3% | 109.8% | ||
| Latest Twelve Months | 4.2% | 39.3% | -13.7% | 3.9% | 15.3% | 109.8% | ||
| Current Trading Multiples | ||||||||
| EV / LTM Revenue | 2.88x | 5.02x | 4.86x | 1.88x | 5.30x | 37.76x | ||
| EV / LTM EBIT | 69.0x | 12.8x | -35.6x | 47.7x | 34.7x | 34.4x | ||
| Price / LTM Sales | 1.46x | 3.76x | 3.54x | 0.58x | 1.99x | 37.72x | ||
| Low | Mid | High | ||||||
| Benchmark EV / LTM Revenue | 1.88x | 4.86x | 5.30x | |||||
| Historical EV / LTM Revenue | 37.76x | 53.34x | 302.54x | |||||
| Selected EV / LTM Revenue | 33.18x | 34.92x | 36.67x | |||||
| (x) LTM Revenue | 67 | 67 | 67 | |||||
| (=) Implied Enterprise Value | 2,211 | 2,327 | 2,444 | |||||
| (-) Non-shareholder Claims * | (3) | (3) | (3) | |||||
| (=) Equity Value | 2,208 | 2,325 | 2,441 | |||||
| (/) Shares Outstanding | 31.1 | 31.1 | 31.1 | |||||
| Implied Value Range | 71.02 | 74.76 | 78.50 | |||||
| FX Rate: TRY/TRY | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 71.02 | 74.76 | 78.50 | 80.85 | ||||
| Upside / (Downside) | -12.2% | -7.5% | -2.9% | |||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | CONSE | KARYE | BIOEN | ZOREN | AYDEM | PAMEL | |
| Enterprise Value | 3,949 | 1,947 | 13,070 | 55,636 | 34,865 | 2,517 | |
| (+) Cash & Short Term Investments | 27 | 55 | 99 | 1,542 | 2,603 | 2 | |
| (+) Investments & Other | 0 | 0 | 319 | 5,752 | 0 | 0 | |
| (-) Debt | (1,979) | (546) | (3,953) | (45,729) | (24,371) | (4) | |
| (-) Other Liabilities | 0 | 0 | (10) | (0) | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 1,997 | 1,456 | 9,525 | 17,200 | 13,097 | 2,514 | |
| (/) Shares Outstanding | 771.0 | 55.0 | 500.0 | 5,000.0 | 698.9 | 31.1 | |
| Implied Stock Price | 2.59 | 26.48 | 19.05 | 3.44 | 18.74 | 80.85 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 2.59 | 26.48 | 19.05 | 3.44 | 18.74 | 80.85 | |
| Trading Currency | TRY | TRY | TRY | TRY | TRY | TRY | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |